



ACADIA Pharmaceuticals to Announce First Quarter 2007 Financial Results on May 8, 2007

May 1, 2007

ACADIA to Host Conference Call and Webcast on Tuesday, May 8, 2007, at 5:00 p.m. Eastern Time

SAN DIEGO--(BUSINESS WIRE)--May 1, 2007--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2007 on Tuesday, May 8, 2007, after the U.S. financial markets close. ACADIA's management will host a conference call and webcast on Tuesday, May 8, 2007 at 5:00 p.m. Eastern Time to discuss ACADIA's financial results and development programs.

The conference call may be accessed by dialing 800-299-7928 for participants in the U.S. or Canada and 617-614-3926 for international callers (reference passcode 99646143). A telephone replay of the conference call may be accessed through May 22, 2007 by dialing 888-286-8010 for callers in the U.S. or Canada and 617-801-6888 for international callers (reference passcode 59529452). The conference call also will be webcast live on ACADIA's website, www.acadia-pharm.com, under the investors section and will be archived there until May 22, 2007.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACADIA currently has five clinical programs as well as a portfolio of preclinical and discovery assets directed at large unmet medical needs, including schizophrenia, Parkinson's disease psychosis, sleep maintenance insomnia, and neuropathic pain. All of the drug candidates in ACADIA's product pipeline emanate from discoveries made using its proprietary drug discovery platform. ACADIA's corporate headquarters is located in San Diego, California and it maintains research and development operations in both San Diego and Malmo, Sweden.

CONTACT: ACADIA Pharmaceuticals Inc.

Lisa Barthelemy, Director, Investor Relations

Thomas H. Aasen, Vice President and Chief Financial Officer

858-558-2871

SOURCE: ACADIA Pharmaceuticals Inc.